No abstract available
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Age Factors
-
Aged
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
Bendamustine Hydrochloride
-
Chlorambucil / administration & dosage
-
Chlorambucil / therapeutic use
-
Combined Modality Therapy
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / therapeutic use
-
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
-
Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Middle Aged
-
Nitrogen Mustard Compounds / administration & dosage
-
Nitrogen Mustard Compounds / therapeutic use
-
Radiotherapy Dosage
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Rituximab
-
Time Factors
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives*
-
Vidarabine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Immunosuppressive Agents
-
Nitrogen Mustard Compounds
-
Chlorambucil
-
Alemtuzumab
-
Rituximab
-
Bendamustine Hydrochloride
-
Vidarabine
-
fludarabine